Zusammenfassung
Die Assoziation zwischen Adipositas und Sexualfunktionsstörungen ist in vielen Studien beschrieben. Neurobiologische, hormonelle und vaskuläre Störungen sowie psychische Erkrankungen gelten bei beiden Geschlechtern als Hauptursachen. Sexuelles Interesse und Verlangen, sexuelle Erregung, Orgasmus, schmerzhafter Geschlechtsverkehr und Ejakulation können betroffen sein. Die Datenlage zu Prävalenzzahlen für Sexualfunktionsstörungen bei adipösen Menschen ist aufgrund der Studien mit kleinen Fallzahlen beschränkt. Für das Screening von Sexualfunktionsstörungen stehen zwei validierte Scores zur Verfügung. Der Internationale Index of Erectile Function-5 (IIEF5), der 15 Fragen enthält und der Female Sexual Function Index (FSFI), der 19 Fragen enthält sind multidimensionale und validierte diagnostische Methoden für das jeweilige Geschlecht. Die Behandlung umfasst Lebensstilveränderungen mit vermehrter körperlicher Aktivität, Gewichtskontrolle, gesunde Ernährung und Beendigung von Tabakkonsum. Testosteron Substitution in Fällen eines nachgewiesenen Hypogonadismus und Therapie mit PDE-5 Inhibitoren sind gut dokumentierte Behandlungsoptionen bei Männern. Therapieoptionen für Frauen sind nicht so gut evaluiert, wobei Fibanserin, Testosteron, Bupropion und Oxytocin wirksam sein dürften.
Summary
The association between obesity and sexual dysfunction has been described in many studies. Neurobiological, hormonal, vascular and mental disturbances are the main reasons in male and in female gender. Sexual interest and desire, sexual arousal, orgasm, painful intercourse and premature ejaculation can be involved. Data for prevalence of sexual function disturbances in obese people are scarce and most studies were small. For screening of sexual function we recommend the International Index of Erectile Function (IIEF)-Score, which contains 15 Items for males and the Female Sexual Function Index (FSFI), which contains 19 items for females. Treatment of sexual function disturbances include lifestyle changes with an increase of physical activity, weight control, healthy eating and smoking cessation. Testosterone substitution in cases of real hypogonadism and treatment with PDE-5 inhibitors are well documented treatment options in male individuals. New treatment options for female patients with variable effectiveness are fibanserin, testosterone, bupropione and oxytocin.
Literatur
Kolotkin RL, Zunker C, Ostbye T. Sexual functioning and obesity: a review. Obesity (Silver Spring). 2012;20(12):2325–33.
Lewis RW, Fugl-Meyer KS, Corona G, et al. Definitions/epidemiology/risk factors for sexual dysfunction. J Sex Med. 2010;7:1598–607.
Laumann EO, Glasser DB, Neves RC, Moreira ED, GSSAB Investigators Group. A population-based survey of sexual activity, sexual problems and associated help-seeking behaviour patterns in mature adults in the United States of America. Int J Impot Res. 2009;21(3):171–8.
Bond DS, Wing RR, Sivamainthan V, et al. Significant resolution of female sexual dysfunction after bariatric surgery. Surg Obes Realt Dis. 2011;7(1):1–7.
Bajos N, Wellings K, Laborde C, Moreau C, CSF Group. Sexuality and obesity, a gender perspective: results from French national random probability survey of sexual behaviours. BMJ 2010;340:c2573.
Dhinsda S, Miller MG, Whirter CL, et al. Testosterone concentrations in diabetic and non diabetic obese men. Diabetes Care. 2010;33:1186–92.
Han TS, Tajar A, O’Neill TW, et al. Impaired quality of life and sexual function in overweight and obese men: the European Male Ageing Study. Eur J Endocrinol. 2011;164:1003–11.
Bhasin Sh, Enzlin P, Covielleo A, Basson R. Sexual dysfunction in men and women with endocrine disorders. Lancet. 2007;369:597–609.
Kinzl JF, Trefalt E, Fiala M, Hotter A, Biebl W, Aigner F. Partnership, sexuality, and sexual disorders in morbidly obese women: consequences of weight loss after gastric banding. Obesity Surg. 2001;11(4):455–8.
Puhl RM, Brownell KD. Confronting and Coping with weight stigma: an investigation of overweight and obese adults. Obesity (Silver Spring). 2006;14(10):1802–15.
Esposito K, Giugliano F, Ciotola M, De Sio M, DÀrmiento M, Giugliano D. Obesity and sexual dysfunction, male and female. Int J Impot Res. 2008;20:358–65.
Pastuszak AW, Badhiwala N, Lipshultz LI, Khera M. Depression is correlated with the psychological and physical aspects of sexual dysfunction in men. Int J Impot Res. 2013;25:194–9.
Harte CB, Meston CM. Association between smoking cessation and sexual health in men. BJU. 2012;109(6):888–96.
Cheng JYW, NG EML, Chen RYL. Physical activity and erectile dysfunction: meta-analysis of population –based studies. Int J Impot Res. 2007;19:245–52.
Katz A. Couples and cancer. Oncol Nurs Forum. 2013;40(2):105.
Rosen R, Riley A, Wagner G, et al. The International Index of Erectile Function (IIEF): a multidimensional scale for assessment of erectile dysfunction. Urology. 1997;49:822–30.
Wiegel M, Meston C, Rosen R. The female sexual function index (FSFI): cross-validation and development of clinical cutoff scores. J Sex Marital Ther. 2005;31(1):1–20.
Dandona P, Dhinsda S. Update: hypogonadotropic hypogonadism in type 2 diabetes and obesity. J Clin Endocrinol Metab. 2011;96:2634–51.
Isidori AM, Giannetta E, Lenzi A. Male hypogonadism. Pituitary. 2008;11(2):171–80.
Mogri M, Dhinsda S, Quattrin T, Ghanim H, Dandona P. Testosterone concentrations in young pubertal and post-pubertal obese males. Clin Endocrinol (Oxf). 2012;78:593–9.
Giagulli VA, Kaufmann JM, Vermeulen A. Pathogenesis of the decreased androgen levels in obese men. J Clin Endocrinol Metab. 1994;79:997–100.
Vermeulen A, Goemaere S, Kaufmann JM. Testosterone body composition and aging. J Endocrinol Invest. 1999;22 Suppl 5:110–6.
Esposito K, Ciotola M, Giugliano F, et al. Association of body weight with sexual function in woman. Int J Impot Res. 2007;19:353–7.
Morotti E, Battaglia B, Paradisi R, et al. Body mass index, stunkard figure rating scale, and sexuality in young italian women: a pilot study. J Sex Med. 2013;10(4):1034–43.
Basson R. Sexual desire and arousal disorders in women. N Engl J Med. 2006;354:1497–506.
Corona G, Ricca V, Bandini E, et al. Selective serotonin reuptake inhibitor-induced sexual dysfunction. J Sex Med. 2009;6(5):1259–69.
Bond DS, Vithiananthan S, Leahey TM, et al. Prevalence and degree of sexual dysfunction in a sample of women seeking bariatric surgery. Surg Obes Relat Dis. 2009;5(6):698–704.
Nicolai MPJ, Liem SS, Both S, et al. A review of the positive and negative effects of cardiovascular drugs on sexual function: a proposed table for use in clinical practice. Neth Heart J. 2014;22:11–9.
Hartmann U. Depression and sexual dysfunction: aspects of a multi-faceted relationship. Psychiatr Prax. 2007;34 Suppl 3:314–17.
Schreiner-Engel P, Schiavi RC. Lifetime psychopathology in individuals with low sexual desire. J Nerv Ment Dis. 1986;174:646–51.
Gregorian RS, Golden KA, Bahce A, Goodman C, Kwong WJ, Khan ZM. Antidepressant-induced sexual dysfunction. Annal Pharmacother. 2002;36:1577–89.
Zajecka J. Strategies for the treatment of antidepressant-induced sexual dysfunction. J Clin Psychiatry. 2001;23:1040–58.
Kinzl JF, Schrattenecker M, Traweger C, Aigner F, Fiala M, Biebl W. Quality of life in morbidly obese patients after surgical weight loss. Obes Surg. 2007;17(2):229–35.
Kinzl JF, Trefalt E, Fiala M, Hotter A, Biebl W, Aigner F. Partnership, sexuality, and sexual disorders in morbidly obese women: consequences of weight loss after gastric banding. Obes Surg 2001;11(4):455–8.
Heidler S, Temml C, Broessner C, et al. Is the metabolic syndrome an independent risk factor for erectile dysfunction? J Urol. 2007;177(2):651–4.
Ponholzer A, Temml C, Mock K, Marszalek M, Obermayr R, Madersbacher S. Prevalence and risk factors for erectile dysfunction in 2869 men using a validated questionnaire. Eur Urol. 2005;47:80–6.
Ponholzer A, Roehlich M, Racz U, Temml C, Madersbacher S. Female sexual dysfunction in a healthy Austrian vohort: prevalence and risk factors. Eur Urol. 2005;47(3):366–74.
Esposito K, Giugliano F, Di Palo C, et al. Effect of lifestyle changes on erectile dysfunction in obese men. JAMA. 2004;291:2978–84.
Hammoud A, Gibson M, Hunt SC, et al. Effect of Roux-en-Y gastric bypass surgery on the sex steroids and quality of life in obese men. J Clin Endocrinol Metab. 2009;94(4):1329–32.
Basson R, Brotto LA. Sexual psychophysiology and effects of sildenafil citrate in oestrogenised women with acquired genital arousal disorder and impaired orgasm: a randomised controlled trial. BJOG. 2003;110:1014–24.
Basson R, McInnes R, Smith MD, Hodgson G, Koppiker N. Efficacy and safety of sildenafil citrate in women with sexual dysfunction associated with female sexual arousal. J Womens Health Gend Based Med. 2002;11:367–77.
Simon JA, Kingsberg SA, Shumel B, et al. Efficacy and safety of fibanserin in postmeopausal women with hypoactive sexual desire disorder: results of the SNOWDROP trial. Menopause. 2014;21:633.
Safarinejad MR, Hosseini SY, Asgari MA, et al. A randomized, double-blind, placebo-controlled study of the efficacy and safety of bupropion for treating hypoactive sexual desire disorder in ovulating women. BJU Int. 2010;106:832.
Muin DA, Woltz M, Marculescu R, et al. Effect of long-term intranasal oxytocin on sexual dysfunction in premenopausal and postmenopausal women: a randomized trial. Fertil Steril. 2015;104(3):715–23.
Günzler C, Berner MM. Efficacy of psychosocial interventions in men and women with sexual dysfunctions – a systematic review of controlled clinical trials: part2 – the efficacy of psychosocial interventions for female sexual dysfunction. J Sex Med. 2012;9(12):3108–25.
Berner M, Günzler C. Efficacy of psychosocial interventions in men and women with sexual dysfunctions – a systematic review of controlled clinical trials: part1 – the efficacy of psychosocial interventions for male sexual dysfunction. J Sex Med. 2012;9(12):3089–107.
Nehra A, Jackson G, Miner M, et al. The Princeton III consensus recommendations for the management of erectile dysfunction and cardiovascular disease. Mayo Clin Proc. 2012;87(8):766–78.
Poggiogalle E, Lazzaro L, Pinto A, Migliaccio S, Lenzi A, Donini LM. Health-related quality of life and quality of sexual life in obese subjects. Int J Endocrinol. 2014;2014:847871. doi:10.1155/2014/847871.
Danksagung
Wir danken A Ponholzer und E Bragnana für die Unterstützung bei der Erstellung dieses Beitrages.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Interessenkonflikt
H. Abrahamian und A. Kautzky-Willer geben an, dass kein Interessenkonflikt besteht.
Rights and permissions
About this article
Cite this article
Abrahamian, H., Kautzky-Willer, A. Sexualität bei Übergewicht und Adipositas. Wien Med Wochenschr 166, 121–128 (2016). https://doi.org/10.1007/s10354-016-0430-9
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s10354-016-0430-9
Schlüsselwörter
- Sexualfunktionsstörungen
- Adipositas
- International Index of Erectile Function-5 (IIEF-5)
- Female Sexual Function Index (FSFI)
- Hypogonadismus